No Data
Grifols' Biotest Set to Launch Intravenous Immunoglobulin in US in Q1 2025
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Grifols Says At End June 2024, Considering SRAAS Proceeds, Leverage Ratio Is Expected To Reach 5.4x Vs. 6.8x In March 2024; FCF In Q2 2024 Expected To Be Positive, Contributing To Reach €5 Million FY24 Guidance, Which Includes €480 Million Of...
Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured Notes And 2027 Term Loan B And On A Pro-Rata Basis...
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value